<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00775138</url>
  </required_header>
  <id_info>
    <org_study_id>TR02-107</org_study_id>
    <nct_id>NCT00775138</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.</brief_title>
  <official_title>A Placebo Controlled, Randomized, Parallel Cohort, Safety And Tolerability Study Of 2 Dose Levels Of Liposomal Amikacin For Inhalation (Arikayce™) In Patients With Bronchiectasis Complicated By Chronic Infection Due To Pseudomonas Aeruginosa.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Insmed Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Insmed Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to determine the safety and tolerability of 28 days of daily dosing of two
      doses (280 mg and 560 mg) of Arikayce™ versus placebo in patients who have bronchiectasis and
      chronic infection due to Pseudomonas infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bronchiectasis is a chronic disorder of the major bronchi and bronchioles characterized by
      permanent dilation, microbial infection, a persistent inflammatory response with the release
      of immune mediators and microbial toxins leading to destruction. The origin of bronchiectasis
      varies, but the presence of microbial infection and a persistent inflammatory response is
      typical of the disease. The chronic nature of the infection and the associated considerable
      morbidity provides the rationale for using aerosolized antibiotics for the treatment of
      bronchiectasis patients.

      This is a multi-national Phase 2 study of safety and tolerability of 28 days of daily dosing
      with two dose levels (280 mg and 560 mg) of Arikayce™ versus placebo in subjects with
      bronchiectasis and chronic Pseudomonas infection. Study subjects will be randomized to
      receive either study drug or placebo by inhalation via a PARI eFlow® nebulizer. Each subject
      will complete 28 days of daily dosing. All study subjects will be followed for microbiologic
      activity for 14 days after completion of treatment and for safety for 28 days post completion
      of study treatment.

      The total study duration will be 56 days, with the screening visit occurring within the
      preceding 14 days prior to study day 1. At Day 1 (baseline), subjects will be evaluated at
      pre-dose and during the first 4-5 hours post-dose. Subjects will return at Week 2 (day 14)
      after start of treatment and at the end of Week 4 (Day 28) treatment period to determine
      safety and efficacy of Arikayce™. Subjects will be followed up on study Days 42 and 56 (about
      2 and 4 weeks after end of treatment) for safety determination. After completion of this
      study, subjects will be followed up for an additional 6 months via phone contacts and records
      review, if hospitalized or treated for pulmonary exacerbation (under the extension protocol).

      Clinical laboratory parameters, audiology testing, clinical adverse events and pulmonary
      function will be evaluated for all study subjects in order to determine the qualitative and
      quantitative safety and tolerability of Arikayce™ compared to placebo. Serum, urine and
      sputum specimens will be collected at periodic intervals to assess pharmacokinetics (PK) in
      subjects who consent for the PK portion of the study. Additionally, sputum samples will be
      collected to determine changes in bacterial density. Total Pulmonary Symptom Severity Score
      (PSSS) will be assessed, and respiratory quality of life will be evaluated by using the St.
      George's Respiratory Questionnaire (SGRQ). Arikace™,Arikayce™, Liposomal Amikacin for
      Inhalation (LAI), and Amikacin Liposome Inhalation Suspension (ALIS) may be used
      interchangeably throughout this study and the other studies evaluating amikacin liposome
      inhalation suspension.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 24, 2008</start_date>
  <completion_date type="Actual">May 11, 2009</completion_date>
  <primary_completion_date type="Actual">May 11, 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting Treatment-emergent AEs (TEAEs) up to End of Treatment</measure>
    <time_frame>Day 1 through 56.</time_frame>
    <description>Number of Subjects reporting TEAE in the Arikayce™ groups and the placebo groups during the study. The table shows the events incidents, not the number of participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-emergent Marked Laboratory Abnormalities up to 28 Days After Study Medication Discontinuation</measure>
    <time_frame>Day 1 through 56.</time_frame>
    <description>Number of subjects reporting Incidence of clinically significant abnormalities in clinical values (Common Terminology Criteria for Adverse Events [CTCAE] grade &gt;= 3) in Arikayce™ and placebo groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-emergent Pulmonary Function Test (PFT) for Acute Tolerability Assessment</measure>
    <time_frame>Pre-dose, 0-1 hour post-dose and 2-4 hours post-dose on day 1, 0-1 hour post-dose and 2-4 hours post-dose on day 14, and 0-1 hour post-dose and 2-4 hours post-dose on day 28</time_frame>
    <description>Changes in PFT from pre-dose during the study were measured on Days 1, 14, and 28. Acute tolerability of the study treatment was assessed by examining the relative (rel.) changes in FEV1 from pre-dose assessments to 0-1 hour post-dose and 2-4 hours post-dose for each time point at which post-dose spirometry was conducted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-emergent PFT Abnormalities up to the End of Study</measure>
    <time_frame>Day 1, Day 14 and Day 28</time_frame>
    <description>Number of Subjects with Decrease of &gt;= 15% in FEV1 (L) from Pre- to Post-dose by Study Day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With an Adverse Event Leading to Permanent Discontinuation of Study Medication</measure>
    <time_frame>Screening to Day 56</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Events up to 28 Days After Study Medication Discontinuation</measure>
    <time_frame>Screening to Day 56</time_frame>
    <description>Number of subjects with a SAE in the Arikace™ groups and the placebo group up to 28 days after study medication discontinuation. See SAE table in the safety section for details.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Log10CFU Per Gram (Density) of Pseudomonas Aeruginosa in Sputum.</measure>
    <time_frame>Baseline to Day 14, Day 28 and Day 42.</time_frame>
    <description>The change in Pseudomonas aeruginosa density from from baseline to Day 14, 28, and 42 were evaluated.Treatment differences with respect to the changes from baseline to each measured study day, defined as the log10 of the sum of all morphotypes (colony-forming units [CFU]) per gram of sputum in (log10CFU/gram [g]), was estimated for each treatment group; standard deviations accompanied the treatment differences.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Pulmonary Symptom Severity Score (PSSS)</measure>
    <time_frame>Baseline to Day 14, Day 28, Day 42 and Day 56.</time_frame>
    <description>Changes in the severity and intensity (frequency x severity) of individual symptoms and change in composite PSSS from baseline to Days 14, 28, 42 and 56.
The Pulmonary Symptom Severity Score (PSSS) was assessed on patient's responses to the Patients Symptoms Questionnaire, which employs symptom frequency and severity scales described for the validated Memorial Symptoms Assessment Scale. Symptom severity was scored on a scale of 0 (not applicable or symptom not present) to 4 (very severe) for each of the 5 symptoms (cough, shortness of breath, sputum production [frequency and severity], fatigue, and wheezing), and a composite score (range, 0 to 20 [low score represents better outcome]) was obtained as the sum of the severity scores for each symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate Change in St. George's Respiratory Questionnaire Measurements</measure>
    <time_frame>Day 1 to Day 14, Day 28, Day 42 and Day 56.</time_frame>
    <description>A composite total score is derived as the sum of domain scores for symptoms, activity, and impact, with 0 as the best possible score and 100 as the worst possible score. A reduction in score of 4 points is generally recognized as a clinically meaningful improvement in quality of life. This analysis compared the changes from Day 1 (prior to first dosing) to Days 14, 28, 42, and 56.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Use of Systemic Antipseudomonal Rescue Therapy</measure>
    <time_frame>Screening to Day 56.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - 280 mg Arikayce™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm of the cohort 1 will receive 280 mg of Arikayce™</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this arm of the cohort 1 will receive matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - 560 mg Arikayce™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm of the cohort 2 will receive 560 mg of Arikayce™</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this arm of the cohort 2 will receive matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>280 mg Arikayce™</intervention_name>
    <description>Study subjects will receive Arikace™ 280 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.</description>
    <arm_group_label>Cohort 1 - 280 mg Arikayce™</arm_group_label>
    <other_name>liposomal amikacin for inhalation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo for Cohort 1</intervention_name>
    <description>Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.</description>
    <arm_group_label>Cohort 1 - Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>560 mg Arikayce™</intervention_name>
    <description>Study subjects will receive Arikace™ 560 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.</description>
    <arm_group_label>Cohort 2 - 560 mg Arikayce™</arm_group_label>
    <other_name>liposomal amikacin for inhalation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo for Cohort 2</intervention_name>
    <description>Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.</description>
    <arm_group_label>Cohort 2 - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female study subjects≥ 18 years of age

          -  Confirmed diagnosis of multi-focal bronchiectasis in two or more lung segments by HRCT
             of the chest

          -  History of chronic infection with P. aeruginosa

          -  Confirmation of infection with P. aeruginosa at screening

          -  SaO2 ≥ 90% at Screening while breathing room air

          -  Ability to comply with study medication use, study visits, and study procedures as
             judged by the investigator

          -  Ability to produce at least 0.5 grams sputum or be willing to undergo an induction to
             produce sputum for clinical evaluation

        Key Exclusion Criteria:

          -  Forced Expiratory Volume in 1 second (FEV1) &lt; 50% of predicted at Screening

          -  Patients with hemoptysis of ≥60 mL within 4 weeks prior to screening

          -  Bronchiectasis due to cystic fibrosis (CF), bronchopulmonary Aspergillus, aspiration
             of foreign body, or secondary to lung compression from tumors

          -  History of non-tuberculous mycobacterial and/or Aspergillus infection requiring
             treatment or treated within 2 years prior to screening

          -  Pulmonary tuberculosis requiring treatment or treated within two years prior to
             screening

          -  History of Lung transplantation

          -  Use of any inhalation or systemic antibiotics (IV antibiotics, or oral antibiotics)
             within 4 weeks prior to Study Day 1

          -  Evidence of biliary cirrhosis with portal hypertension

          -  Smoking tobacco or any substance within 6 months prior to screening, and throughout
             the study

          -  History of alcohol, medication, or illicit drug abuse within the 1 year prior to
             screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gina Eagle, MD</last_name>
    <role>Study Director</role>
    <affiliation>Insmed Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mosdos</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manipal</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rabka Zdrój</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nis</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>October 15, 2008</study_first_submitted>
  <study_first_submitted_qc>October 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2008</study_first_posted>
  <results_first_submitted>April 3, 2019</results_first_submitted>
  <results_first_submitted_qc>June 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 10, 2019</results_first_posted>
  <disposition_first_submitted>September 29, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>September 29, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 3, 2016</disposition_first_posted>
  <last_update_submitted>June 20, 2019</last_update_submitted>
  <last_update_submitted_qc>June 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bronchiectasis</keyword>
  <keyword>Respiratory Infections</keyword>
  <keyword>Amikacin</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Respiratory Tract Infections</keyword>
  <keyword>Lung Diseases</keyword>
  <keyword>Pseudomonas aeruginosa</keyword>
  <keyword>Amikacin liposome inhalation suspension (ALIS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Pseudomonas Infections</mesh_term>
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amikacin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arikayce™ at 280 mg</title>
          <description>Study subjects will receive Arikayce™ 280 mg on Days 1-28.</description>
        </group>
        <group group_id="P2">
          <title>Matching Placebo (280 mg)</title>
          <description>Study subjects will receive matching placebo on Days 1-28.</description>
        </group>
        <group group_id="P3">
          <title>Arikayce™ at 560 mg</title>
          <description>Study subjects will receive Arikayce™ 560 mg on Days 1-28.</description>
        </group>
        <group group_id="P4">
          <title>Matching Placebo (560 mg)</title>
          <description>Study subjects will receive matching placebo on Days 1-28.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Modified intent-to-treat (mITT) population, defined as all randomized patients who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Arikayce™ at 280 mg</title>
          <description>Study subjects will receive Arikayce™ 280 mg on Days 1-28.</description>
        </group>
        <group group_id="B2">
          <title>Matching Placebo (280 mg)</title>
          <description>Study subjects will receive matching placebo on Days 1-28.</description>
        </group>
        <group group_id="B3">
          <title>Arikayce™ at 560 mg</title>
          <description>Study subjects will receive Arikayce™ 560 mg on Days 1-28.</description>
        </group>
        <group group_id="B4">
          <title>Matching Placebo (560 mg)</title>
          <description>Study subjects will receive matching placebo on Days 1-28.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="19"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.9" spread="21.1"/>
                    <measurement group_id="B2" value="46.8" spread="15.0"/>
                    <measurement group_id="B3" value="58.5" spread="16.0"/>
                    <measurement group_id="B4" value="52.3" spread="11.1"/>
                    <measurement group_id="B5" value="52.4" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Treatment-emergent AEs (TEAEs) up to End of Treatment</title>
        <description>Number of Subjects reporting TEAE in the Arikayce™ groups and the placebo groups during the study. The table shows the events incidents, not the number of participants.</description>
        <time_frame>Day 1 through 56.</time_frame>
        <population>Safety population, the same as the mITT population, defined as all randomized patients who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Arikace™ 280 mg</title>
            <description>Study subjects will receive Arikace™ 280 mg on Days 1-28.</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo (280 mg)</title>
            <description>Study subjects will receive matching placebo on Days 1-28.</description>
          </group>
          <group group_id="O3">
            <title>Arikace™ 560 mg</title>
            <description>Study subjects will receive Arikace™ 560 mg on Days 1-28.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo (560 mg)</title>
            <description>Study subjects will receive matching placebo on Days 1-28.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Treatment-emergent AEs (TEAEs) up to End of Treatment</title>
          <description>Number of Subjects reporting TEAE in the Arikayce™ groups and the placebo groups during the study. The table shows the events incidents, not the number of participants.</description>
          <population>Safety population, the same as the mITT population, defined as all randomized patients who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Productive Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronchial disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoptysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wheezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasopharyngitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aphthous stomatitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cervicobrachial syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic obstructive pulmonary disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysgeusia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysphonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Forced expiratory volume decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pharyngolaryngeal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhinorrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sinus bradycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tinnitus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toothache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper respiratory tract infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anorexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronchiectasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abortion incomplete</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood creatinine increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Laryngitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung abscess</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Palpitations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Treatment-emergent Marked Laboratory Abnormalities up to 28 Days After Study Medication Discontinuation</title>
        <description>Number of subjects reporting Incidence of clinically significant abnormalities in clinical values (Common Terminology Criteria for Adverse Events [CTCAE] grade &gt;= 3) in Arikayce™ and placebo groups.</description>
        <time_frame>Day 1 through 56.</time_frame>
        <population>The safety population is the mITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arikace™ 280 mg</title>
            <description>Study subjects will receive Arikace™ 280 mg on Days 1-28.</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo (280 mg)</title>
            <description>Study subjects will receive matching placebo on Days 1-28.</description>
          </group>
          <group group_id="O3">
            <title>Arikace™ 560 mg</title>
            <description>Study subjects will receive Arikace™ 560 mg on Days 1-28.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo (560 mg)</title>
            <description>Study subjects will receive matching placebo on Days 1-28.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-emergent Marked Laboratory Abnormalities up to 28 Days After Study Medication Discontinuation</title>
          <description>Number of subjects reporting Incidence of clinically significant abnormalities in clinical values (Common Terminology Criteria for Adverse Events [CTCAE] grade &gt;= 3) in Arikayce™ and placebo groups.</description>
          <population>The safety population is the mITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leukocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils Abs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Treatment-emergent Pulmonary Function Test (PFT) for Acute Tolerability Assessment</title>
        <description>Changes in PFT from pre-dose during the study were measured on Days 1, 14, and 28. Acute tolerability of the study treatment was assessed by examining the relative (rel.) changes in FEV1 from pre-dose assessments to 0-1 hour post-dose and 2-4 hours post-dose for each time point at which post-dose spirometry was conducted.</description>
        <time_frame>Pre-dose, 0-1 hour post-dose and 2-4 hours post-dose on day 1, 0-1 hour post-dose and 2-4 hours post-dose on day 14, and 0-1 hour post-dose and 2-4 hours post-dose on day 28</time_frame>
        <population>The analysis population is the safety population, the same as the mITT population, defined as all randomized patients who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Arikace™ 280 mg</title>
            <description>Study subjects will receive Arikace™ 280 mg on Days 1-28.</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo (280 mg)</title>
            <description>Study subjects will receive matching placebo on Days 1-28.</description>
          </group>
          <group group_id="O3">
            <title>Arikace™ 560 mg</title>
            <description>Study subjects will receive Arikace™ 560 mg on Days 1-28.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo (560 mg)</title>
            <description>Study subjects will receive matching placebo on Days 1-28.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-emergent Pulmonary Function Test (PFT) for Acute Tolerability Assessment</title>
          <description>Changes in PFT from pre-dose during the study were measured on Days 1, 14, and 28. Acute tolerability of the study treatment was assessed by examining the relative (rel.) changes in FEV1 from pre-dose assessments to 0-1 hour post-dose and 2-4 hours post-dose for each time point at which post-dose spirometry was conducted.</description>
          <population>The analysis population is the safety population, the same as the mITT population, defined as all randomized patients who received at least 1 dose of study drug.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1: Pre-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.917" spread="0.793"/>
                    <measurement group_id="O2" value="1.841" spread="0.536"/>
                    <measurement group_id="O3" value="1.939" spread="0.515"/>
                    <measurement group_id="O4" value="1.758" spread="0.654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 0 - 1 Hr Post-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.922" spread="0.780"/>
                    <measurement group_id="O2" value="1.820" spread="0.546"/>
                    <measurement group_id="O3" value="1.907" spread="0.475"/>
                    <measurement group_id="O4" value="1.807" spread="0.666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 2 - 4 Hrs Post-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.955" spread="0.766"/>
                    <measurement group_id="O2" value="1.864" spread="0.520"/>
                    <measurement group_id="O3" value="1.912" spread="0.477"/>
                    <measurement group_id="O4" value="1.812" spread="0.675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1:0-1 Hr Post-Dose Rel. Change from Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.816" spread="9.317"/>
                    <measurement group_id="O2" value="-1.186" spread="3.028"/>
                    <measurement group_id="O3" value="-0.873" spread="9.640"/>
                    <measurement group_id="O4" value="3.128" spread="12.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1:2-4 Hrs Post-Dose Rel. Change from Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.323" spread="11.181"/>
                    <measurement group_id="O2" value="1.484" spread="3.507"/>
                    <measurement group_id="O3" value="-0.661" spread="8.374"/>
                    <measurement group_id="O4" value="3.082" spread="11.671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14: Pre-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.892" spread="0.759"/>
                    <measurement group_id="O2" value="1.761" spread="0.550"/>
                    <measurement group_id="O3" value="1.864" spread="0.607"/>
                    <measurement group_id="O4" value="1.895" spread="0.592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14: 0 - 1 Hr Post-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.907" spread="0.776"/>
                    <measurement group_id="O2" value="1.794" spread="0.556"/>
                    <measurement group_id="O3" value="1.856" spread="0.555"/>
                    <measurement group_id="O4" value="1.908" spread="0.611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14: 2 - 4 Hr Post-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.931" spread="0.771"/>
                    <measurement group_id="O2" value="1.797" spread="0.520"/>
                    <measurement group_id="O3" value="1.843" spread="0.567"/>
                    <measurement group_id="O4" value="1.901" spread="0.542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day14:0-1 Hr Post-Dose Rel. Change from Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.800" spread="8.818"/>
                    <measurement group_id="O2" value="2.061" spread="4.509"/>
                    <measurement group_id="O3" value="-1.629" spread="9.961"/>
                    <measurement group_id="O4" value="0.589" spread="4.558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day14:2-4 Hr Post-Dose Rel. Change from Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.388" spread="9.020"/>
                    <measurement group_id="O2" value="2.711" spread="6.620"/>
                    <measurement group_id="O3" value="-3.114" spread="8.506"/>
                    <measurement group_id="O4" value="1.228" spread="9.617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: Pre-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.919" spread="0.761"/>
                    <measurement group_id="O2" value="1.794" spread="0.507"/>
                    <measurement group_id="O3" value="1.846" spread="0.532"/>
                    <measurement group_id="O4" value="1.934" spread="0.560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: 0 - 1 Hr Post-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.928" spread="0.751"/>
                    <measurement group_id="O2" value="1.803" spread="0.502"/>
                    <measurement group_id="O3" value="1.797" spread="0.541"/>
                    <measurement group_id="O4" value="1.901" spread="0.550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: 2 - 4 Hrs Post-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.908" spread="0.754"/>
                    <measurement group_id="O2" value="1.809" spread="0.527"/>
                    <measurement group_id="O3" value="1.799" spread="0.578"/>
                    <measurement group_id="O4" value="1.940" spread="0.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28:0-1 Hr Post-Dose Rel. Change from Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.635" spread="7.647"/>
                    <measurement group_id="O2" value="0.654" spread="3.675"/>
                    <measurement group_id="O3" value="0.607" spread="4.185"/>
                    <measurement group_id="O4" value="-1.437" spread="6.454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28:2-4 Hrs Post-Dose Rel. Change from Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.356" spread="8.858"/>
                    <measurement group_id="O2" value="0.601" spread="3.184"/>
                    <measurement group_id="O3" value="-0.006" spread="6.156"/>
                    <measurement group_id="O4" value="-0.542" spread="7.690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Treatment-emergent PFT Abnormalities up to the End of Study</title>
        <description>Number of Subjects with Decrease of &gt;= 15% in FEV1 (L) from Pre- to Post-dose by Study Day</description>
        <time_frame>Day 1, Day 14 and Day 28</time_frame>
        <population>The analysis population is the safety population, the same as the mITT population, defined as all randomized patients who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Arikace™ 280 mg</title>
            <description>Study subjects will receive Arikace™ 280 mg on Days 1-28.</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo (280 mg)</title>
            <description>Study subjects will receive matching placebo on Days 1-28.</description>
          </group>
          <group group_id="O3">
            <title>Arikace™ 560 mg</title>
            <description>Study subjects will receive Arikace™ 560 mg on Days 1-28.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo (560 mg)</title>
            <description>Study subjects will receive matching placebo on Days 1-28.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-emergent PFT Abnormalities up to the End of Study</title>
          <description>Number of Subjects with Decrease of &gt;= 15% in FEV1 (L) from Pre- to Post-dose by Study Day</description>
          <population>The analysis population is the safety population, the same as the mITT population, defined as all randomized patients who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With an Adverse Event Leading to Permanent Discontinuation of Study Medication</title>
        <time_frame>Screening to Day 56</time_frame>
        <population>The analysis population is the safety population, the same as the mITT population, defined as all randomized patients who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Arikace™ 280 mg</title>
            <description>Study subjects will receive Arikace™ 280 mg on Days 1-28.</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo (280 mg)</title>
            <description>Study subjects will receive matching placebo on Days 1-28.</description>
          </group>
          <group group_id="O3">
            <title>Arikace™ 560 mg</title>
            <description>Study subjects will receive Arikace™ 560 mg on Days 1-28.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo (560 mg)</title>
            <description>Study subjects will receive matching placebo on Days 1-28.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With an Adverse Event Leading to Permanent Discontinuation of Study Medication</title>
          <population>The analysis population is the safety population, the same as the mITT population, defined as all randomized patients who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serious Adverse Events up to 28 Days After Study Medication Discontinuation</title>
        <description>Number of subjects with a SAE in the Arikace™ groups and the placebo group up to 28 days after study medication discontinuation. See SAE table in the safety section for details.</description>
        <time_frame>Screening to Day 56</time_frame>
        <population>The safety population is the modified intent-to-treat (mITT) population, defined as all randomized patients who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Arikace™ 280 mg</title>
            <description>Study subjects will receive Arikace™ 280 mg on Days 1-28.</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo (280 mg)</title>
            <description>Study subjects will receive matching placebo on Days 1-28.</description>
          </group>
          <group group_id="O3">
            <title>Arikace™ 560 mg</title>
            <description>Study subjects will receive Arikace™ 280 mg on Days 1-28.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo (560 mg)</title>
            <description>Study subjects will receive matching placebo on Days 1-28.</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events up to 28 Days After Study Medication Discontinuation</title>
          <description>Number of subjects with a SAE in the Arikace™ groups and the placebo group up to 28 days after study medication discontinuation. See SAE table in the safety section for details.</description>
          <population>The safety population is the modified intent-to-treat (mITT) population, defined as all randomized patients who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Log10CFU Per Gram (Density) of Pseudomonas Aeruginosa in Sputum.</title>
        <description>The change in Pseudomonas aeruginosa density from from baseline to Day 14, 28, and 42 were evaluated.Treatment differences with respect to the changes from baseline to each measured study day, defined as the log10 of the sum of all morphotypes (colony-forming units [CFU]) per gram of sputum in (log10CFU/gram [g]), was estimated for each treatment group; standard deviations accompanied the treatment differences.</description>
        <time_frame>Baseline to Day 14, Day 28 and Day 42.</time_frame>
        <population>Per source, this is the Pa population, which includes patients who grew Pa on day 1, analyzed as treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Arikace™ 280 mg</title>
            <description>Study subjects will receive Arikace™ 280 mg on Days 1-28.</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo (280 mg)</title>
            <description>Study subjects will receive matching placebo on Days 1-28.</description>
          </group>
          <group group_id="O3">
            <title>Arikace™ 560 mg</title>
            <description>Study subjects will receive Arikace™ 560 mg on Days 1-28.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo (560 mg)</title>
            <description>Study subjects will receive matching placebo on Days 1-28.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Log10CFU Per Gram (Density) of Pseudomonas Aeruginosa in Sputum.</title>
          <description>The change in Pseudomonas aeruginosa density from from baseline to Day 14, 28, and 42 were evaluated.Treatment differences with respect to the changes from baseline to each measured study day, defined as the log10 of the sum of all morphotypes (colony-forming units [CFU]) per gram of sputum in (log10CFU/gram [g]), was estimated for each treatment group; standard deviations accompanied the treatment differences.</description>
          <population>Per source, this is the Pa population, which includes patients who grew Pa on day 1, analyzed as treated.</population>
          <units>log10CFU per gram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14 Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.227" spread="0.805"/>
                    <measurement group_id="O2" value="-0.333" spread="0.515"/>
                    <measurement group_id="O3" value="-2.016" spread="1.942"/>
                    <measurement group_id="O4" value="-0.474" spread="1.942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.094" spread="0.975"/>
                    <measurement group_id="O2" value="0.315" spread="0.732"/>
                    <measurement group_id="O3" value="-1.013" spread="1.099"/>
                    <measurement group_id="O4" value="-0.302" spread="0.443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42 Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.101" spread="0.788"/>
                    <measurement group_id="O2" value="-0.057" spread="0.627"/>
                    <measurement group_id="O3" value="0.046" spread="0.705"/>
                    <measurement group_id="O4" value="-0.641" spread="1.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Pulmonary Symptom Severity Score (PSSS)</title>
        <description>Changes in the severity and intensity (frequency x severity) of individual symptoms and change in composite PSSS from baseline to Days 14, 28, 42 and 56.
The Pulmonary Symptom Severity Score (PSSS) was assessed on patient's responses to the Patients Symptoms Questionnaire, which employs symptom frequency and severity scales described for the validated Memorial Symptoms Assessment Scale. Symptom severity was scored on a scale of 0 (not applicable or symptom not present) to 4 (very severe) for each of the 5 symptoms (cough, shortness of breath, sputum production [frequency and severity], fatigue, and wheezing), and a composite score (range, 0 to 20 [low score represents better outcome]) was obtained as the sum of the severity scores for each symptom.</description>
        <time_frame>Baseline to Day 14, Day 28, Day 42 and Day 56.</time_frame>
        <population>The safety population is used for this analysis. It is the same as the mITT population, defined as all randomized patients who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Arikace™ 280 mg</title>
            <description>Study subjects will receive Arikace™ 280 mg on Days 1-28.</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo (280 mg)</title>
            <description>Study subjects will receive matching placebo on Days 1-28.</description>
          </group>
          <group group_id="O3">
            <title>Arikace™ 560 mg</title>
            <description>Study subjects will receive Arikace™ 560 mg on Days 1-28.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo (560 mg)</title>
            <description>Study subjects will receive matching placebo on Days 1-28.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Pulmonary Symptom Severity Score (PSSS)</title>
          <description>Changes in the severity and intensity (frequency x severity) of individual symptoms and change in composite PSSS from baseline to Days 14, 28, 42 and 56.
The Pulmonary Symptom Severity Score (PSSS) was assessed on patient's responses to the Patients Symptoms Questionnaire, which employs symptom frequency and severity scales described for the validated Memorial Symptoms Assessment Scale. Symptom severity was scored on a scale of 0 (not applicable or symptom not present) to 4 (very severe) for each of the 5 symptoms (cough, shortness of breath, sputum production [frequency and severity], fatigue, and wheezing), and a composite score (range, 0 to 20 [low score represents better outcome]) was obtained as the sum of the severity scores for each symptom.</description>
          <population>The safety population is used for this analysis. It is the same as the mITT population, defined as all randomized patients who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14 change from Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.125" spread="2.213"/>
                    <measurement group_id="O2" value="-0.200" spread="0.789"/>
                    <measurement group_id="O3" value="-0.471" spread="2.035"/>
                    <measurement group_id="O4" value="-0.250" spread="2.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 change from Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.167" spread="2.988"/>
                    <measurement group_id="O2" value="0.000" spread="2.357"/>
                    <measurement group_id="O3" value="-1.000" spread="4.087"/>
                    <measurement group_id="O4" value="-0.125" spread="4.257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42 change from Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.458" spread="3.476"/>
                    <measurement group_id="O2" value="-1.000" spread="1.491"/>
                    <measurement group_id="O3" value="-1.882" spread="4.285"/>
                    <measurement group_id="O4" value="1.125" spread="3.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56 change from Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.458" spread="2.874"/>
                    <measurement group_id="O2" value="-1.500" spread="2.121"/>
                    <measurement group_id="O3" value="-2.167" spread="3.053"/>
                    <measurement group_id="O4" value="-2.000" spread="1.690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate Change in St. George's Respiratory Questionnaire Measurements</title>
        <description>A composite total score is derived as the sum of domain scores for symptoms, activity, and impact, with 0 as the best possible score and 100 as the worst possible score. A reduction in score of 4 points is generally recognized as a clinically meaningful improvement in quality of life. This analysis compared the changes from Day 1 (prior to first dosing) to Days 14, 28, 42, and 56.</description>
        <time_frame>Day 1 to Day 14, Day 28, Day 42 and Day 56.</time_frame>
        <population>The analysis population is the mITT population, defined as all randomized patients who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Arikace™ 280 mg</title>
            <description>Study subjects will receive Arikace™ 280 mg on Days 1-28.</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo (280 mg)</title>
            <description>Study subjects will receive matching placebo on Days 1-28.</description>
          </group>
          <group group_id="O3">
            <title>Arikace™ 560 mg</title>
            <description>Study subjects will receive Arikace™ 560 mg on Days 1-28.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo (560 mg)</title>
            <description>Study subjects will receive matching placebo on Days 1-28.</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate Change in St. George's Respiratory Questionnaire Measurements</title>
          <description>A composite total score is derived as the sum of domain scores for symptoms, activity, and impact, with 0 as the best possible score and 100 as the worst possible score. A reduction in score of 4 points is generally recognized as a clinically meaningful improvement in quality of life. This analysis compared the changes from Day 1 (prior to first dosing) to Days 14, 28, 42, and 56.</description>
          <population>The analysis population is the mITT population, defined as all randomized patients who received at least one dose of study medication.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14 change from Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.024" spread="8.558"/>
                    <measurement group_id="O2" value="-6.350" spread="8.756"/>
                    <measurement group_id="O3" value="-6.101" spread="12.164"/>
                    <measurement group_id="O4" value="-2.807" spread="7.256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 change from Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.205" spread="13.661"/>
                    <measurement group_id="O2" value="-5.812" spread="12.039"/>
                    <measurement group_id="O3" value="-6.200" spread="11.855"/>
                    <measurement group_id="O4" value="-8.304" spread="12.993"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42 change from Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.611" spread="13.274"/>
                    <measurement group_id="O2" value="-6.130" spread="14.271"/>
                    <measurement group_id="O3" value="-8.196" spread="12.332"/>
                    <measurement group_id="O4" value="0.242" spread="5.818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56 change from Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.937" spread="16.281"/>
                    <measurement group_id="O2" value="-7.371" spread="11.270"/>
                    <measurement group_id="O3" value="-9.282" spread="10.302"/>
                    <measurement group_id="O4" value="-1.637" spread="15.161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Use of Systemic Antipseudomonal Rescue Therapy</title>
        <time_frame>Screening to Day 56.</time_frame>
        <population>The analysis population is the mITT population, defined as all randomized patients who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Arikace™ 280 mg</title>
            <description>Study subjects will receive Arikace™ 280 mg on Days 1-28.</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo (280mg)</title>
            <description>Study subjects will receive matching placebo on Days 1-28.</description>
          </group>
          <group group_id="O3">
            <title>Arikace™ 560 mg</title>
            <description>Study subjects will receive Arikace™ 560 mg on Days 1-28.</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo (560 mg)</title>
            <description>Study subjects will receive matching placebo on Days 1-28.</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Use of Systemic Antipseudomonal Rescue Therapy</title>
          <population>The analysis population is the mITT population, defined as all randomized patients who received at least one dose of study medication</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Rescue Medication Initiation by Day 28</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rescue Medication Initiation by Day 56</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Rescue Medication Initiation</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>TEAEs were assessed at Baseline and all subsequent study visits up to day 56</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arikace at 280 mg</title>
          <description>Study subjects will receive Arikace™ 280 mg on Days 1-28.</description>
        </group>
        <group group_id="E2">
          <title>Matching Placebo (280 mg)</title>
          <description>Study subjects will receive matching placebo on Days 1-28.</description>
        </group>
        <group group_id="E3">
          <title>Arikace at 560 mg</title>
          <description>Study subjects will receive Arikace™ 560 mg on Days 1-28.</description>
        </group>
        <group group_id="E4">
          <title>Matching Placebo (560 mg)</title>
          <description>Study subjects will receive matching placebo on Days 1-28.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion Incomplete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Lung Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aphthous Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Heart Rate Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="21" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Cervicobrachial Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Productive Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="11" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Bronchial Disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kevin Mange, Sr. Vice President, Clinical Development</name_or_title>
      <organization>Insmed</organization>
      <phone>908-947-2651</phone>
      <email>Kevin.Mange@Insmed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

